ClinicalTrials.gg
CompletedNCT00821834CLEANUpdated Jul 26, 2011

Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned

A Phase 3 interventional study of clopidogrel (SR25990) and ticlopidine in Stable Angina and Myocardial Infarction, sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-07-26.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,003
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing clopidogrel in Angina, Stable — none open to participants now, none under way, none of them phase 3. Clopidogrel · Angina, Stable.

Enrollment
Largest of 10
1,003 · median 281
Started
2008
with 2 others
Phase 3
4 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
1 of 10
Sanofi

Among the 10 studies testing clopidogrel in Angina, Stable, this one has the largest enrollment, is one of 3 that started in 2008, is one of 4 in phase 3, and was the 4th registered.

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 57 are open to participants now.

Browse Angina, Stable studies →

Open to participants now

None of the 10 studies testing clopidogrel in Angina, Stable is open now. The open studies under Angina, Stable, anywhere →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Angina, Stable studies recruiting now, 33 (85%) set no upper age limit and 2 (5%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing clopidogrel in Angina, Stable as a file.
02

Study summary

Primary objective:

  • To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interest in patients with stable angina (SA) or old myocardial infarction (OMI) to which percutaneous coronary intervention (PCI) is being planned.

Secondary objectives:

  • To compare the incidence of adverse events, adverse drug reactions and bleeding events in patients treated with clopidogrel versus ticlopidine.
  • To compare the incidence of major adverse cardiac events (MACE) and major adverse cardiac and cerebrovascular events (MACCE) in patients treated with clopidogrel versus ticlopidine.
  • To evaluate the long-term safety (adverse drug reactions, adverse events, safety events of interest and bleeding events) of clopidogrel for a total of 52 weeks;
  • To evaluate MACE and MACCE of clopidogrel for a total of 52 weeks.
Read the detailed description

The study consisted of two periods:

  • a double blind treatment period of 12 weeks followed by,
  • an open label clopidogrel treatment period in a subset of patients.

All patients should receive aspirin (81-100 mg once daily) as a background therapy during investigational product administration.

03

Conditions studied

  • Stable Angina
  • Myocardial Infarction

Keywords

  • Old Myocardial infarction
  • Platelet Aggregation Inhibitors
  • Angioplasty
  • Transluminal
  • Percutaneous Coronary
  • Stents
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Stable Angina / Old Myocardial Infarction patients who met all of the following criteria:

  • Myocardial ischemic finding was proven within 2 months before randomization,
  • Either ≥ 75% stenosis documented by CAG or severe stenosis confirmed by multi-slice computerized tomography (MSCT) angiography within 1 month before randomization,
  • PCI was being planned.

Exclusion criteria

Exclusion Criteria:

  • Planned coronary artery bypass graft (CABG), emergent/urgent PCI, or staged PCI,
  • 3-vessel coronary artery disease with significant lesions in each vessel,
  • Planned PCI associated with 6 or more stent placements,
  • Not less than 50% stenosis of the left main coronary artery,
  • Chronic total occlusion (CTO),
  • Saphenous vein graft (SVG).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,003 participants (actual)

Study arms

  • Experimental
    Clopidogrel

    Patients received: * clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose, * ticlopidine matching placebo twice daily.

    Drug: clopidogrel (SR25990) · Drug: Placebo

  • Active comparator
    Ticlopidine

    Patients received: * ticlopidine 100 mg twice daily, * clopidogrel matching placebo once daily.

    Drug: ticlopidine · Drug: Placebo

Interventions

  • Form: tablets Route: oral

  • Drugticlopidine

    Form: tablets Route: oral

  • DrugPlacebo

    Form: tablets Route: oral

06

What researchers measure

Primary outcomes

  1. Time from randomization to first safety events of interest

    Safety events of interest were: * Clinically significant bleeding, * Leukopenia, neutropenia or thrombocytopenia occurring as adverse drug reaction, * Elevated liver function values occurring as adverse drug reaction, * Permanent investigational product discontinuation due to skin disorders, gastrointestinal disorders, bleeding, hepatic disorders, or significant decreases in such tests as leukocytes, neutrophils or platelets occurring as adverse drug reaction.

    Time frame: 12 Weeks (duble blind treatment period)

Secondary outcomes

  1. Time from randomization to first Major Adverse Cardiac Events (MACE)

    MACE included: * All- cause mortality, * Acute myocardial infarction, * Revascularization (excluding revascularization related to the planned PCI), * Stent thrombosis

    Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)

  2. Time from randomization to first bleeding events

    Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)

  3. Time from randomization to first Adverse Events / Adverse Drug Reactions

    Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)

  4. Time from randomization to first Major Adverse Cardiac and Cerebrovascular Events (MACCE)

    MACCE included: * All- cause mortality, * Acute myocardial infarction, * Revascularization (excluding revascularization related to the planned PCI), * Stent thrombosis, * Ischemic stroke.

    Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2009
First posted
Jan 14, 2009
Start
Dec 2008
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Last update
Jul 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00821834
Lead sponsor
Sanofi
First posted
Jan 14, 2009
Start date
Dec 2008
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Jul 26, 2011

Study contacts

Takaaki Issiki, PhD/FACC
principal investigator · Division of Cardiology, Dpt of Medicine, Teikyo University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion